Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.22.2.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of stock option activity
The following is a summary of option activities under the Company’s 2014 Plan for the six months ended June 30, 2022:
Number of
Shares		 Weighted
Average
Exercise Price		 Weighted
Average
Remaining
Contractual
Term (Years)		 Aggregate Intrinsic Value
Outstanding, December 31, 2021 35,405,000  $ 0.07  9.08 $ 134,750 
Granted 4,350,000  0.04 
Exercised —  — 
Cancelled (321,250) 0.06 
Forfeited (1,678,750) 0.08 
Outstanding, June 30, 2022 37,755,000  $ 0.07  8.7 $ — 
Exercisable, June 30, 2022 12,066,250  $ 0.08  8.02 $ — 
Schedule of fair value assumptions of stock option granted
The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:

Six Months Ended
June 30, 2022
Dividend yield —  %
Volatility factor
126.3 - 132.6%
Risk-free interest rate
2.89 - 3.60%
Expected term (years)
5.00 - 6.08
Schedule of RSA activity
The following is a summary of restricted stock activity outside of the Company’s 2014 Plan during the six months ended June 30, 2022:
Number of
Shares		 Weighted
Average
Grant
Date Fair
Value
Unvested, December 31, 2021 150,000  $ 0.13 
Released (150,000) 0.13 
Unvested, June 30, 2022 —  $ — 
Schedule of stock-based compensation expense The Company recognized stock-based compensation expense, including compensation expense for warrants with vesting provisions issued to a service provider (Note 4), and the RSUs discussed above, in its Condensed Consolidated Statements of Comprehensive Loss as follows:
Three Months Ended June 30, Six Months Ended
June 30,
2022 2021 2022 2021
Research and development $ 21,955  $ 13,612  $ 40,541  $ 19,363 
General and administrative 122,409  98,087  241,181  238,916 
$ 144,364  $ 111,699  $ 281,722  $ 258,279